Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t

  • 30articles · 30d
  • 11+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 97%with images
  • 336avg words
articles per day
Categories
  • Medical 23
  • Health & Wellness 20
  • Health 13
  • Economy, Business & Finance 11
  • Business & Industrial 6
  • Science & Technology 5
  • Finance & Business 4
  • News 4

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BiotechDispatch
biotechdispatch.com.au > news > dimerix-takes-control-of-us-development-pathway-for-new-kidney-injury-treatment

Dimerix takes control of US development pathway for new kidney injury treatment

3+ week, 6+ day ago   (311+ words) Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652..., giving the Australian biotechnology company direct control of clinical development plans for its newly...complete, allowing Dimerix to become sponsor of the existing US IND and…...

BiotechDispatch
biotechdispatch.com.au > news > neurizon-therapeutics-appoints-chris-bremer-as-chief-executive-to-steer-als-drug-through-final-t

Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial

1+ week, 14+ hour ago   (504+ words) stage BiotechDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug...with more than two decades of pharmaceutical leadership experience, most of it built at the German drug...The company's lead drug candidate, NUZ-001, is being tested…...

BiotechDispatch
biotechdispatch.com.au > news > us-health-agency-funds-broad-access-trial-for-melbourne-biotechs-als-drug

US health agency funds broad access trial for Melbourne biotech's ALS drug

5+ day, 9+ hour ago   (444+ words) grant, announced by Neurizon, will finance an Expanded Access Protocol for NUZ-001, the company's lead drug...designed for patients who are otherwise ineligible to join formal clinical trials, offering access to the drug...the arrangement, Neurizon will serve as the…...

BiotechDispatch
biotechdispatch.com.au > news > medical-developments-confirms-building-momentum-as-penthrox-sales-grow

Medical Developments confirms building momentum as Penthrox sales grow

3+ week, 4+ day ago   (655+ words) Medical Developments International reported higher profitability and stronger cash generation, with accelerating...Medical Developments said the move added about $1 million to 2026 earnings....Medical Developments said the findings further differentiated the product from standard care and could...The strongest strategic development…...

BiotechDispatch
biotechdispatch.com.au > news > prescient-reaches-key-ptx-100-trial-checkpoint-ahead-of-december-review

Prescient reaches key PTX-100 trial checkpoint ahead of December review

1+ week, 4+ day ago   (338+ words) experts that will assess safety and efficacy data from both arms before advising on the next stage of development...The drug is intended to inhibit geranylgeranyl transferase-1, an enzyme involved in cancer-related signalling...PTX-100 has already received US Food and…...

Google News
biotechdispatch.com.au > news > avecho-moves-to-deepen-global-partnering-push-as-cbd-insomnia-program-advances

Avecho moves to deepen global partnering push as CBD insomnia program advances - Biotech

2+ week, 6+ day ago   (418+ words) Biotechnology has appointed senior pharmaceutical executive Eve Williamson as a strategic business development...Williamson most recently served as vice president and global head of business development at CSL, where...She brings more than 20 years of experience in pharmaceutical business development…...

BiotechDispatch
biotechdispatch.com.au > news > biotron-advances-hepatitis-b-candidate-towards-human-trials-after-promising-hbv-and-hdv-results

Biotron advances hepatitis B candidate towards human trials after promising HBV and HDV results

3+ week, 6+ day ago   (423+ words) Biotron is preparing to advance its hepatitis B drug candidate into formal preclinical development after...plans to undertake formal good laboratory practice preclinical studies and manufacture a GMP-grade drug...A second experiment tested the two drugs together....

BiotechDispatch
biotechdispatch.com.au > news > australian-biotech-immuron-takes-gut-health-treatment-to-the-us-market

Australian biotech Immuron takes gut health treatment to the US market

1+ week, 14+ hour ago   (359+ words) PROIBS is classified as a medical device rather than a drug, designed to ease abdominal pain, bloating...Kisker, chief executive and founder of Calmino Group AB, said the US agreement represents a natural evolution...

BiotechDispatch
biotechdispatch.com.au > news > arovella-therapeutics-moves-off-the-shelf-cell-therapy-from-lab-to-patients

Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients

1+ week, 14+ hour ago   (412+ words) said manufacturing the product to clinical standard while meeting requirements set by the US Food and Drug...

BiotechDispatch
biotechdispatch.com.au > news > telix-reports-strong-growth-as-late-stage-cancer-pipeline-advances

Telix reports strong growth as late-stage cancer pipeline advances

3+ week, 4+ day ago   (548+ words) in 2031, strengthening its capacity to fund commercial expansion, manufacturing investment and development-stage...Research and development expenditure rose to US$124 million during the half, with US$68 million invested...

Web

External web results are waiting for the human check. Complete the press-and-hold control above. Google advertising and AI choices remain separate after verification.